10x Genomics (TXG) Stock Price, News & Analysis

Company Overview

10x Genomics (NASDAQ: TXG) is a life sciences technology company specializing in high-resolution genomic analysis. Since its founding in 2012 and headquartered in Pleasanton, California, the company has developed proprietary platforms that enable researchers to study biological systems at single-cell and spatial resolution. By integrating microfluidics, molecular barcoding and advanced bioinformatics, 10x Genomics provides tools that help scientists uncover cellular heterogeneity and molecular interactions across diverse tissue types.

The company’s flagship Chromium platform supports single-cell RNA sequencing, single-cell immune profiling and single-cell assay for transposase-accessible chromatin (scATAC-seq). In addition to the Chromium system, 10x Genomics offers the Visium Spatial Gene Expression solution, which allows researchers to map gene activity within tissue sections. These products are complemented by software pipelines and analytical tools that facilitate data processing, visualization and interpretation, making complex genomic data accessible to both academic and industrial researchers.

10x Genomics serves a global customer base that spans academic institutions, biotechnology firms, pharmaceutical companies and government research laboratories. Its instruments and reagents are distributed through direct sales teams in North America, Europe and parts of Asia, with additional collaborations and distribution partners extending its reach to emerging markets. The company also invests in customer support and training programs, hosting workshops and webinars to help users adopt and optimize its technologies for diverse research applications.

Under the leadership of co-founder and Chief Executive Officer Serge Saxonov, 10x Genomics has expanded its product portfolio and scaled its operations to meet growing demand for single-cell and spatial analysis. Saxonov, who co-founded the company after a career in software engineering, has guided 10x Genomics through multiple product launches and its initial public offering. The executive team’s focus on innovation and strategic partnerships continues to drive the company’s mission to transform biological research and accelerate discoveries in health and disease.

Key Stats

• Today's Range: $12.43 to $12.43
• 50-Day Range: $8.10 to $13.01
• 52-Week Range: $6.78 to $24.76
• Volume: 1,566 shs
• Average Volume: 2.73 million shs
• Market Capitalization: $1.50 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.13
• Consensus Rating: Hold

10x Genomics Stock Analysis - MarketRank™

10x Genomics scored higher than 93% of companies evaluated by MarketBeat, and ranked 66th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

10x Genomics has received a consensus rating of Hold. The company's average rating score is 2.46, and is based on 7 buy ratings, 5 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

10x Genomics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for 10x Genomics are expected to grow in the coming year, from ($1.43) to ($1.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of 10x Genomics is -9.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of 10x Genomics is -9.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

10x Genomics has a P/B Ratio of 2.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

12.04% of the float of 10x Genomics has been sold short.

Short Interest Ratio / Days to Cover

10x Genomics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in 10x Genomics has recently decreased by 16.17%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

10x Genomics does not currently pay a dividend.

Dividend Growth

10x Genomics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.8 / 5
• Environmental Score: -0.73

Percentage of Shares Shorted

12.04% of the float of 10x Genomics has been sold short.

Short Interest Ratio / Days to Cover

10x Genomics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in 10x Genomics has recently decreased by 16.17%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

10x Genomics has a news sentiment score of 1.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for 10x Genomics this week, compared to 7 articles on an average week.

Search Interest

4 people have searched for TXG on MarketBeat in the last 30 days.

MarketBeat Follows

4 people have added 10x Genomics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, 10x Genomics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $173,238.00 in company stock.

Percentage Held by Insiders

Only 9.39% of the stock of 10x Genomics is held by insiders.

Percentage Held by Institutions

84.68% of the stock of 10x Genomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TXG Stock Analysis - Frequently Asked Questions

How have TXG shares performed this year?

10x Genomics' stock was trading at $14.36 at the beginning of 2025. Since then, TXG shares have decreased by 15.7% and is now trading at $12.10.

How were 10x Genomics' earnings last quarter?

10x Genomics (NASDAQ:TXG) released its quarterly earnings results on Thursday, May, 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.09. 10x Genomics's quarterly revenue was down 2.3% compared to the same quarter last year.
Read the conference call transcript.

When did 10x Genomics IPO?

10x Genomics (TXG) raised $297 million in an initial public offering (IPO) on Thursday, September 12th 2019. The company issued 9,000,000 shares at $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Cowen was co-manager.

Who are 10x Genomics' major shareholders?

Top institutional shareholders of 10x Genomics include Pallas Capital Advisors LLC (0.05%), Kera Capital Partners Inc. (0.03%) and Parallel Advisors LLC. Insiders that own company stock include Serge Saxonov, Benjamin J Hindson, John R Stuelpnagel, Adam Taich, Mathai Mammen, Justin J Mcanear, James Wilbur and Alan Mateo.
View institutional ownership trends.

How do I buy shares of 10x Genomics?

Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of 10x Genomics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that 10x Genomics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), PayPal (PYPL), Advanced Micro Devices (AMD) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/10/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:TXG
• CIK: 1770787
• Web: www.10xgenomics.com
• Phone: 925-401-7300
• Fax: N/A
• Employees: 1,240
• Year Founded: N/A

Price Target and Rating

• Average Price Target for 10x Genomics: $14.13
• High Price Target: $24.00
• Low Price Target: $6.50
• Potential Upside/Downside: +16.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.46
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$182.63 million
• Net Margins: -25.14%
• Pretax Margin: -24.56%
• Return on Equity: -23.22%
• Return on Assets: -18.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.37
• Quick Ratio: 4.68

Sales & Book Value

• Annual Sales: $610.78 million
• Price / Sales: 2.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.81 per share
• Price / Book: 2.08

Miscellaneous

• Outstanding Shares: 123,130,000
• Free Float: 111,572,000
• Market Cap: $1.49 billion
• Optionable: Optionable
• Beta: 2.03